New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date. We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as … [Read more...]
Current Number Of Lawsuits Filed In The Four Diabetes Drugs Federal Court MDL Cases
From the February 15, 2018 version of this document, “MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending” (accessed 2/21/18), published by the United States Judicial Panel on Multidistrict Litigation (JPML), we get the current number of cases filed in each of the four federal court Multidistrict Litigation (MDL) cases … [Read more...]
Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2) inhibitor class, such as canagliflozin (Invokana / Invokamet), empagliflozin (Jardiance / Glyxambi / Synjardy), and dapagliflozin (Farxiga / Xigduo / … [Read more...]
Could Invokana have been the cause of my lower-limb amputation?
The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]